- stimulates vascular vasopressin V1 receptors to cause vasoconstriction; tends to not cause hypertension in normotensive patients
- stimulates vasopressin V2 receptors in the renal tubules to cause fluid retention and prevent fluid loss
- no alpha or beta adrenergic receptor activity thus may be effective in vasodilatory shock unresponsive to catecholamines or in the presence of acidosis/hypoxia, and will enhance myocardial oxygen delivery without an increase in consumption
- treatment of septic shock: 0.09 to 1.8 u/hr. Do not titrate, run at fixed dose.
- organ donor management : 0.09 to 1.8 u/hr. Do not titrate, run at fixed dose.
- refractory pulseless cardiac arrest: 40 units IV X 1
50 units in 50 ml D5W or NS
- hypovolemia, hypoxemia and acidosis should be corrected concurrently with initiation of therapy
- should be weaned off
cramping, nausea, vomiting, eructation, diarrhea
- vasopressin + ganglionic blocking agents = increased vasopressin pressor effect
- vasopressin + lithium = decreased antidiuretic activity
- vasopressin + carbamazepine = increased antidiuretic activity
urine output, BUN, creatinine
changes in skin colour or temperature
chest pain, diarrhea, abdominal pain
- May be administered by IV infusion by an approved nurse in CCTC.
- Must be administered via a central line.
- Continuous infusion must be administered via an infusion pump.
- Should not be infused via the proximal injectate port (blue) of the Swan Ganz catheter.
- Patient requires placement of an arterial line to monitor BP.